文献速递白血病MDS 与骨髓增殖性肿瘤

急性髓系白血病骨髓微环境的高多重蛋白质组学评估

Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究采用基于适配体的高多重亲和蛋白质组学平台(SOMAscan)分析急性髓系白血病(AML)患者(n=10)与年龄性别匹配健康对照(n=10)骨髓非细胞区室的蛋白质组。发现168种蛋白丰度显著差异(91上调、77下调),以IL-8等细胞因子/趋化因子信号网络最突出,并首次报道CCL23在AML和MDS中显著升高且功能实验支持其抑制正常造血。

要点

  • 骨髓非细胞区室蛋白质组学可揭示AML微环境特征,血液蛋白质组或骨髓RNA测序替代性欠佳。
  • AML骨髓中168种蛋白显著差异,91上调、77下调,IL-8相关细胞因子/趋化因子网络最突出。
  • CCL23在AML和MDS患者中显著升高,功能实验支持其抑制正常造血。

核心结论

  • AML患者骨髓非细胞区室存在显著蛋白质组改变,以细胞因子/趋化因子网络为突出特征。
  • CCL23在AML和MDS中显著升高,功能实验支持其抑制正常造血。

研究设计与样本

  • 采用基于适配体的高多重亲和蛋白质组学平台(SOMAscan)分析骨髓非细胞区室。
  • 纳入AML患者(n=10)与年龄性别匹配健康对照(n=10)。
  • 比较血液蛋白质组和骨髓RNA测序作为替代筛查策略的适用性。

主要发现

  • 168种蛋白在白血病骨髓中丰度显著差异,其中91种上调、77种下调。
  • IL-8等细胞因子和趋化因子构成高度连接的信号网络,为最突出蛋白质组特征。
  • 首次报道CCL23(髓系祖细胞抑制因子-1)在AML和MDS患者中显著升高。
  • 功能实验支持CCL23在抑制正常造血中的作用。

临床怎么用

  • 提示评估AML骨髓微环境时,血液蛋白质组或骨髓RNA测序可能不足以替代骨髓蛋白质组学。
  • CCL23可能作为AML和MDS中抑制正常造血的候选分子,需进一步验证。

局限性

  • 样本量较小(AML和对照各10例)。
  • 需进一步研究验证蛋白质组学发现及CCL23的功能机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a genetically heterogeneous disease that is characterized by abnormal clonal proliferation of myeloid progenitor cells found predominantly within the bone marrow (BM) and blood. Recent studies suggest that genetic and phenotypic alterations in the BM microenvironment support leukemogenesis and allow leukemic cells to survive and evade chemotherapy-induced death. However, despite substantial evidence indicating the role of tumor-host interactions in AML pathogenesis, little is known about the complex microenvironment of the BM. To address this, we performed novel proteomic profiling of the noncellular compartment of the BM microenvironment in patients with AML (n = 10) and age- and sex-matched healthy control subjects (n = 10) using an aptamer-based, highly multiplexed, affinity proteomics platform (SOMAscan). We show that proteomic assessment of blood or RNA-sequencing of BM are suboptimal alternate screening strategies to determine the true proteomic composition of the extracellular soluble compartment of AML patient BM. Proteomic analysis revealed that 168 proteins significantly differed in abundance, with 91 upregulated and 77 downregulated in leukemic BM. A highly connected signaling network of cytokines and chemokines, including IL-8, was found to be the most prominent proteomic signature associated with AML in the BM microenvironment. We report the first description of significantly elevated levels of the myelosuppressive chemokine CCL23 (myeloid progenitor inhibitory factor-1) in both AML and myelodysplastic syndrome patients and perform functional experiments supportive of a role in the suppression of normal hematopoiesis. This unique paired RNA-sequencing and proteomics data set provides innovative mechanistic insights into AML and healthy aging and should serve as a useful public resource.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Çelik H, Lindblad KE, Popescu B, et al. Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. Blood Adv. 2020. PMID: 31985806. doi:10.1182/bloodadvances.2019001124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。